NEWS

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7^TM with Merck’s KEYTRUDA^® in Triple-Negative Breast Cancer

FDA Grants Orphan Drug Designation Status to NeoImmuneTech’s Hyleukin-7 for Idiopathic CD4+ Lymphocytopenia Treatment

NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7^TM in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers

NeoImmuneTech Presents Hyleukin-7^TM and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting

NeoImmuneTech Announces Initiation of Clinical Trial for Hyleukin-7^TM Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients

NeoImmuneTech Strengthens Senior Management with the Appointment of NgocDeip Le, M.D., Ph.D., as Medical Officer

Hyleukin-7^TM Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA^®

NeoImmuneTech Announces Initiation of Hyleukin-7^TM Clinical Development for Cancer Patients in the U.S.

NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7^TM in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers